Institut Stvolovykh Kletok Cheloveka PAO - ESG Rating & Company Profile powered by AI
The webpage includes a questions and answers table about Institut Stvolovykh Kletok Cheloveka PAO. Browse to the end of this page for potential risks for Institut Stvolovykh Kletok Cheloveka PAO based on sector, location and marketcap. If you work at Institut Stvolovykh Kletok Cheloveka PAO and you wish to use your ESG aseessment, please contact us.
Institut Stvolovykh Kletok Cheloveka PAO in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.0
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 36 | Repligen Corp | 8.1 | High |
| 36 | Zealand Pharma A/S | 8.1 | High |
| 55 | Institut Stvolovykh Kletok Cheloveka PAO | 8.0 | High |
| 55 | Abbott India Ltd | 8.0 | High |
| 55 | Amrutanjan Health Care Ltd | 8.0 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Institut Stvolovykh Kletok Cheloveka PAO have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO disclose current and historical energy intensity?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO report the average age of the workforce?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO disclose its ethnicity pay gap?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO disclose cybersecurity risks?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO offer flexible work?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO conduct supply chain audits?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO conduct 360 degree staff reviews?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO disclose the individual responsible for D&I?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO disclose water use targets?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO have careers partnerships with academic institutions?
Sign up for free to unlockDid Institut Stvolovykh Kletok Cheloveka PAO have a product recall in the last two years?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO disclose incidents of discrimination?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Institut Stvolovykh Kletok Cheloveka PAO issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO disclose parental leave metrics?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO disclose the pay ratio of women to men?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Institut Stvolovykh Kletok Cheloveka PAO involved in embryonic stem cell research?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO disclose its waste policy?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO report according to TCFD requirements?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO disclose energy use targets?
Sign up for free to unlockDoes Institut Stvolovykh Kletok Cheloveka PAO disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Institut Stvolovykh Kletok Cheloveka PAO have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Institut Stvolovykh Kletok Cheloveka PAO
These potential risks are based on the size, segment and geographies of the company.
Public Joint-Stock Company "Human Stem Cells Institute' operates as a biotech company primarily in Russia. The company engages in the drug discovery, research and development, and marketing of proprietary products and services in the field of regenerative medicine; bio-insurance; medical genetics, including reproductive genetics; gene therapy; and biopharmaceutics. It owns and operates Gemabank, a family cord blood stem cell bank in Russia and the CIS; and Reprobank, a reproductive cell and tissue bank for personal storage of reproductive cells and tissues, as well as a sperm/oocyte donation. The company also offers Neovasculgen, a gene-therapy drug for treatment of peripheral arterial disease, including critical limb ischemia; and SPRS-therapy (service for personal regeneration of skin), a set of personalized diagnostics and treatment procedures for repairing skin damages. In addition, it operates GENETICO, a medical genetics center and molecular diagnostic lab that provides a range of genetic analysis and counseling services for the early detection, prediction, and prophylactic treatment of genetic disorders, including reproductive system diseases; and provides preimplantation genetic diagnosis and screening that includes testing of developing embryos for monogenic inherited diseases and chromosome abnormalities during an in vitro fertilization cycle. Further, the company offers non-invasive prenatal testing of fetal chromosome abnormalities; and develops Gemacell, a cell-based drug candidate for treatment of myocardial infarction. Additionally, it provides range of diagnostic services for identification of genetic predisposition to oncological diseases; and distributes cell processing equipment. The company was founded in 2003 and is based in Moscow, Russia. Public Joint-Stock Company "Human Stem Cells Institute' is a subsidiary of PJSC International Medical Center Processings and Kriokhraneniya of Biomaterialy.